Q4

QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, FY, EPS, QuidelOrtho, Hagens Berman, COVID-19, SAN, Q4, Person, Pharmaceutical industry

SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .
  • 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.
  • Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.
  • “We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Sonata Software: International Services Dollar revenue for FY'24 of 323.6 Mn grew 34.3% YoY; Domestic business delivered Gross contribution for FY'24 of 260.4 Cr 18.6% YoY growth in INR; The Board recommends a final dividend of ₹ 4.40 per share (FY'24 tot

Retrieved on: 
Martedì, Maggio 7, 2024
USD, Quarter, CRS, Yoy, Health care, MD, TMT, Digital, Microsoft, PAT, BFSI, TTH, Q4, Pension fund

EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%

Key Points: 
  • EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%
    PAT for Q4'24 stood at ₹ 70.3 Crores; QoQ de-growth of 18.2%.
  • Revenues for FY'24 at ₹ 5950.5 crores; YoY growth of 7.4%
    Gross contribution for Q4'24 at ₹ 64.8 Crs de-grew by 9.1% QoQ.
  • Gross contribution for FY'24 at ₹ 260.4 Crs grew by 18.6% YoY
    EBITDA for Q4'24 at ₹ 56.2 crores; QoQ de-growth of 4.5%.
  • EBITDA for FY'24 at ₹ 228.3 crores; YoY growth of 16.0%
    PAT for Q4'24 at ₹ 40.1 crores; QoQ de-growth of 5.9%.

Sonata Software: International Services Dollar revenue for FY'24 of 323.6 Mn grew 34.3% YoY; Domestic business delivered Gross contribution for FY'24 of 260.4 Cr 18.6% YoY growth in INR; The Board recommends a final dividend of ₹ 4.40 per share (FY'24 tot

Retrieved on: 
Martedì, Maggio 7, 2024
USD, Quarter, CRS, Yoy, Health care, MD, TMT, Digital, Microsoft, PAT, BFSI, TTH, Q4, Pension fund

EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%

Key Points: 
  • EBITDA for FY'24 at ₹ 627.7 crores; YoY growth of 30.2%
    PAT for Q4'24 stood at ₹ 70.3 Crores; QoQ de-growth of 18.2%.
  • Revenues for FY'24 at ₹ 5950.5 crores; YoY growth of 7.4%
    Gross contribution for Q4'24 at ₹ 64.8 Crs de-grew by 9.1% QoQ.
  • Gross contribution for FY'24 at ₹ 260.4 Crs grew by 18.6% YoY
    EBITDA for Q4'24 at ₹ 56.2 crores; QoQ de-growth of 4.5%.
  • EBITDA for FY'24 at ₹ 228.3 crores; YoY growth of 16.0%
    PAT for Q4'24 at ₹ 40.1 crores; QoQ de-growth of 5.9%.

QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Retrieved on: 
Venerdì, Maggio 3, 2024
FDA, FY, QuidelOrtho, Hagens Berman, COVID-19, Q4, EPS, Person, Pharmaceutical industry

In addition, QuidelOrtho’s Adjusted EBITDA came in 28% below the analysts’ consensus expectations and the company slashed its 2024 endemic COVID-19 revenue guidance to $200 million.

Key Points: 
  • In addition, QuidelOrtho’s Adjusted EBITDA came in 28% below the analysts’ consensus expectations and the company slashed its 2024 endemic COVID-19 revenue guidance to $200 million.
  • 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.
  • Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.
  • “We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Retrieved on: 
Giovedì, Aprile 25, 2024
FDA, FY, QuidelOrtho, Hagens Berman, COVID-19, Q4, EPS, Person, Pharmaceutical industry

In addition, QuidelOrtho’s Adjusted EBITDA came in 28% below the analysts’ consensus expectations and the company slashed its 2024 endemic COVID-19 revenue guidance to $200 million.

Key Points: 
  • In addition, QuidelOrtho’s Adjusted EBITDA came in 28% below the analysts’ consensus expectations and the company slashed its 2024 endemic COVID-19 revenue guidance to $200 million.
  • 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.
  • Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.
  • “We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ADSK Investors with Substantial Losses to Contact Firm’s Attorneys Investigating Possible Securities Law Violations

Retrieved on: 
Martedì, Aprile 23, 2024
Attention, FY, Hagens Berman, Annual report, ADSK, News, Q4, Person, Disclosure, Cryptocurrency

SAN FRANCISCO, April 23, 2024 (GLOBE NEWSWIRE) --  - Hagens Berman urges Autodesk, Inc. (NASDAQ: ADSK) investors who suffered substantial losses to submit your losses now.

Key Points: 
  • Autodesk, Inc. (ADSK) Falls After Delaying Annual Report, Contacting SEC – Hagens Berman
    SAN FRANCISCO, April 23, 2024 (GLOBE NEWSWIRE) --  - Hagens Berman urges Autodesk, Inc. (NASDAQ: ADSK) investors who suffered substantial losses to submit your losses now .
  • 2, 2024, the price of Autodesk shares significantly fell after the software company announced that it was probing its own accounting practices.
  • The disclosure has prompted prominent investor rights firm, Hagens Berman, to open an investigation in possible violations of the U.S. Securities laws.
  • “We are investigating the propriety of Autodesk’s internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

QDEL INVESTOR ALERT: Securities Fraud Class Action Filed After QuidelOrtho (QDEL) Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Retrieved on: 
Lunedì, Aprile 22, 2024
FDA, FY, EPS, QuidelOrtho, Hagens Berman, COVID-19, SAN, Q4, Person, Pharmaceutical industry

SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .
  • 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.
  • Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.
  • “We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Autodesk, Inc. (ADSK) Falls After Delaying Annual Report, Contacting SEC – Hagens Berman

Retrieved on: 
Giovedì, Aprile 18, 2024
Attention, FY, Hagens Berman, Annual report, ADSK, SAN, News, Q4, Person, Disclosure, Cryptocurrency

2, 2024, the price of Autodesk shares significantly fell after the software company announced that it was probing its own accounting practices.

Key Points: 
  • 2, 2024, the price of Autodesk shares significantly fell after the software company announced that it was probing its own accounting practices.
  • The disclosure has prompted prominent investor rights firm, Hagens Berman, to open an investigation in possible violations of the U.S. Securities laws.
  • 2, when Autodesk announced that it would not timely file its annual report for the year ended Jan. 31, 2024.
  • “We are investigating the propriety of Autodesk’s internal controls over financial reporting,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Retrieved on: 
Mercoledì, Aprile 17, 2024
FDA, FY, EPS, QuidelOrtho, Hagens Berman, COVID-19, SAN, Q4, Person, Pharmaceutical industry

SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .
  • 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.
  • Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.
  • “We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

QuidelOrtho (QDEL) Securities Fraud Class Action Filed After QDEL Reports Disastrous Q4 2023 Results, Terminates CEO, Withdraws FDA Submission - Hagens Berman

Retrieved on: 
Sabato, Aprile 13, 2024
FDA, FY, EPS, QuidelOrtho, Hagens Berman, COVID-19, SAN, Q4, Person, Pharmaceutical industry

SAN FRANCISCO, April 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, April 13, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges QuidelOrtho Corporation (NASDAQ: QDEL) investors who suffered substantial losses to submit your losses now .
  • 2, 2024, QuidelOrtho announced that it withdrew its submission for the Savanna RVP4 Test because recent data failed to meet expectations.
  • Since Feb. 13, 2024, the price of QuidelOrtho shares has fallen $24.59, or nearly 37%, wiping out about $1.6 billion of shareholder value.
  • “We are investigating whether QuidelOrtho may have engaged in improper channel-stuffing and about the likelihood of FDA approval for the Savanna test,” said Reed Kathrein, the Hagens Berman partner leading the investigation.